RxDoctor Payments Data

Brandi Browning, APRN

Nurse Practitioner · Lexington, KYNPI 1164166823

Payments from drug & device makers

$703in general payments, 2019–2025

Across 39 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$425
  • Vanda Pharmaceuticals Inc.$92
  • GSK$48
  • Amgen$38
  • AstraZeneca$32
  • Biogen$23
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$703100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$703 in reported general payments places this provider in the 60th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,023
Medicare patients
41
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide92$122,084
OzempicSemaglutide64$87,045
EliquisApixaban29$39,841
JardianceEmpagliflozin24$27,856
FarxigaDapagliflozin Propanediol26$26,231
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$25,970
JanuviaSitagliptin Phosphate20$25,503
TrulicityDulaglutide15$22,020
MyrbetriqMirabegron23$20,383
LinzessLinaclotide26$20,059
Janumet XrSitagliptin Phos/Metformin Hcl18$17,067
XareltoRivaroxaban17$15,250
RybelsusSemaglutide13$11,839
Cyclosporine13$7,232
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$5,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$15$144,104107 claims
GSKTrelegy Ellipta, Arnuity Ellipta$48$28,88038 claims
AstraZenecaFarxiga$32$26,23126 claims
AbbVieLinzess$425$20,05926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →